Nitroglycerin (NTG) plus whole intracranial radiotherapy for brain metastases (BM) in non-small cell cancer patient (NSCLC): A randomized open label, phase II clinical trial.

Oscar Gerardo Arrieta-Rodriguez,Norma Hernández-Pedro,Federico Maldonado,Maritza Ramos,Masao Yamamoto-Ramos,Diego López,Francisco Lozano,Zyanya Lucía Zatarain-Barrón,Graciela Cruz-Rico,Pedro Barrios-Bernal,Mario Orozco-Morales,Bernardo Cacho,Diana Flores-Estrada,Andres Felipe Cardona Zorrilla,Christian Rolfo

Nitroglycerin (NTG) plus whole intracranial radiotherapy for brain metastases (BM) in non-small cell cancer patient (NSCLC): A randomized open label, phase II clinical trial.

2021

Oscar Gerardo Arrieta-Rodriguez
Norma Hernández-Pedro
Federico Maldonado
Maritza Ramos
Masao Yamamoto-Ramos
Diego López
Francisco Lozano
Zyanya Lucía Zatarain-Barrón
Graciela Cruz-Rico
Pedro Barrios-Bernal
Mario Orozco-Morales
Bernardo Cacho
Diana Flores-Estrada
Andres Felipe Cardona Zorrilla
Christian Rolfo

9114Background: Hypoxia has been associated with chemo-radioresistance secondary to Vascular Endothelial Growth Factor Receptor induced by Hypoxia Induced Factor (HIF). Nitroglycerin (NTG) can redu...

Keywords:

Medicine
non small cell cancer
Oncology
open label
Hypoxia (medical)
Internal medicine
Radiation therapy
Vascular Endothelial Growth Factor Receptor
Clinical trial

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations